Following successful examination, the synthesis process used to create nature-identical MenaQ7 PharmaPure Vitamin K2 as menaquinone-7 (MK-7) received patents in Israel (patent #238199), the United States (patent #14/435,260) and Australia (patent #2013330517), according to a press statement from the product’s maker, NattoPharma ASA’s (Oslow, Norway, and Metuchen, NJ).
MenaQ7 Vitamin K2 is the best-documented vitamin K2 available as MK-7, the company says, with guaranteed actives and stability as well as clinical substantiation. The newly patented synthesis process makes it “the world’s only truly all-trans synthetic Vitamin K2 as MK-7,” said William Sommer, vice president of global development & regulatory, NattoPharma. That matters because all-trans MK-7 is more bioavailable and bioactive than its cis isomer.
That the product is currently being evaluated in two studies “sponsored by the traditional medical community” is “evidence that the medical community recognizes the difference a vitamin can make for human health,” Sommer continued, “and in selecting MenaQ7 PharmaPure, they want to use the purest, all-trans material for future further confirmation and discovery of health benefits.”